Research Perspectives:

Towards precision oncology in angiosarcomas using next generation “omic” technologies

Grace Fangmin Tan and Jason Yongsheng Chan _

PDF  |  Full Text  |  How to cite

Oncotarget. 2021; 12:1953-1955. https://doi.org/10.18632/oncotarget.27996

Metrics: PDF 783 views  |   Full Text 1692 views  |   ?  


Grace Fangmin Tan1 and Jason Yongsheng Chan1,2

1 Division of Medical Oncology, National Cancer Centre Singapore, Singapore

2 Oncology Academic Clinical Program, Duke-NUS Medical School, Singapore

Correspondence to:

Jason Yongsheng Chan, email: [email protected]

Keywords: rare cancer; single cell sequencing; chemoresistance; spatial transcriptomics

Received: March 31, 2021     Accepted: June 10, 2021     Published: September 14, 2021

Copyright: © 2021 Tan and Chan. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Angiosarcomas are a group of aggressive tumors of vascular origin. Although thought to be a rare cancer constituting just 1–2% of all soft tissue sarcomas, recent observations suggest that angiosarcomas are more common amongst Asian populations as compared to the West, suggesting the possibility of distinct genetic or environmental triggers influencing its pathogenesis. Advances in genomic sequencing efforts have led to the discovery of ultraviolet mutation signatures and high tumor mutation burden as common features of angiosarcoma of the head and neck. In addition, multi-omic analyses integrated with clinical data identified 3 subtypes characterized by distinctive etiological and biological phenotypes, with potential implications on precision therapy. The systemic and local immune milieu, as well as the presence of “giant” tumor cells, was also recently demonstrated to influence clinical behavior and patient outcomes, further highlighting complexities of this disease. Improvements in next generation “omic”-based technologies are expected to improve our understanding of angiosarcoma and guide the development of precision oncology in this rare cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27996